India, April 21 -- Calidi Biotherapeutics Inc. (CLDI), a clinical-stage biotechnology company, released on Monday new data on the approach of simultaneous T-cell activation and expression of T-cell engagers in the tumor microenvironment at the 2026 annual meeting of the American Association of Cancer Research (AACR).
Calidi has been developing the RedTail virotherapy platform, consisting of viruses that target tumors while modifying the tumor microenvironment (TME), enabling a high-level expression of therapeutic genetic payloads directly at the tumor sites.
Data released by the company indicates that RedTail viruses express T-cell engagers and target solid tumor cells by T-cell activation. Historically, while T-cell engagers showed effic...